icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
zwLh0ZyUcB4vN8yX